PATH | VRL
Menu

Seroefficacy of Vi Polysaccharide–Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV)

This article, published in Clinical Infectious Diseases, reports the results of a study that estimated the efficacy of the Typbar-TCV® typhoid conjugate vaccine in an endemic setting. The results showed that Typbar-TCV substantially reduced the number of serologically defined clinical or subclinical infections in infants, children, and adults. These results support the 2017 Strategic Advisory Group of Experts on Immunization’s recommendation for deployment of typhoid conjugate vaccines in high-burden areas. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Voysey M, Pollard AJ

Published: 2018

» Visit web page (English)

(Located at academic.oup.com)

Citation: Voysey M, Pollard AJ. Seroefficacy of Vi Polysaccharide–Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). Clinical Infectious Diseases. 2018;67(1):18-24.

Resource types: Peer-reviewed journal

Diseases/vaccines: Typhoid

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Global